Mirena (Levonorgestrel)

Levonorgestrel released from the IUS binds to progesterone receptors in the endometrium, suppressing ovulation, thickening cervical mucus, and inducing endometrial atrophy. These actions together prevent fertilisation and implantation, while also reducing menstrual blood loss.

Mirena is supplied as a single 52 mg intrauterine system that releases approximately 20 µg of levonorgestrel per day. The prescriber determines the appropriate device placement and duration, typically up to five years of use.

Mirena is contraindicated in pregnancy (Category X) and must be removed if pregnancy occurs. For breastfeeding women, insertion after delivery is generally considered safe, but patients should discuss timing and any concerns with their healthcare provider.

To order Mirena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative is a copper IUD, which provides non‑hormonal contraception. Mirena offers hormonal regulation, reducing menstrual bleeding and providing additional therapeutic benefits, whereas copper IUDs may increase bleeding. Choice depends on patient preference, medical history and desired side‑effect profile.

Mirena should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its integrity until insertion.

Mirena is inserted by a trained healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting after confirming uterine position and ruling out pregnancy.

Serious risks include uterine perforation during insertion, device expulsion, pelvic inflammatory disease, and the rare possibility of ectopic pregnancy if conception occurs. Prompt medical evaluation is required if severe abdominal pain, abnormal bleeding or signs of infection develop.

Mirena should not be used by women who are currently pregnant, have active pelvic infection, untreated sexually transmitted disease, uterine anomalies, known or suspected breast cancer, severe liver disease, or a history of thromboembolic disorders. Contraindications must be confirmed by a healthcare professional.